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NALP proteins, also known as NLRPs, belong to the CATERPILLER
protein family involved, like Toll-like receptors, in the recognition
of microbial molecules and the subsequent activation of inflam-
matory and immune responses. Current advances in the function of
NALPs support the recently proposed model of a disease contin-
uum bridging autoimmune and autoinflammatory disorders.
Among these diseases, hereditary periodic fevers (HPFs) are Men-
delian disorders associated with sequence variations in very few
genes; these variations are mostly missense mutations whose
deleterious effect, which is particularly difficult to assess, is often
questionable. The growing number of identified sporadic cases of
periodic fever syndrome, together with the lack of discriminatory
clinical criteria, has greatly hampered the identification of new
disease-causing genes, a step that is, however, essential for ap-
propriate management of these disorders. Using a candidate gene
approach, we identified nonambiguous mutations in NALP12 (i.e.,
nonsense and splice site) in two families with periodic fever
syndromes. As shown by means of functional studies, these two
NALP12 mutations have a deleterious effect on NF-B signaling.
Overall, these data identify a group of HPFs defined by molecular
defects in NALP12, opening up new ways to manage these disor-
ders. The identification of these first NALP12 mutations in patients
with autoinflammatory disorder also clearly demonstrates the
crucial role of NALP12 in inflammatory signaling pathways,
thereby assigning a precise function to this particular member of
an emerging family of proteins whose putative biological proper-
ties are currently inferred essentially through in vitro means.
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The hereditary periodic fevers (HPFs) consist of a group ofMendelian autoinflammatory disorders characterized by re-
current episodes of fever and systemic inflammation, sometimes
complicated by amyloidosis. Based on clinical criteria, six dif-
ferent disorders have been defined: familial Mediterranean fever
(FMF), TNF receptor-associated periodic syndrome (TRAPS),
hyper IgD with periodic fever syndrome (HIDS), familial cold
autoinflammatory syndrome (FCAS), Muckle-Wells syndrome
(MWS), and chronic infantile neurological cutaneous and artic-
ular (CINCA) syndrome, also known as neonatal-onset multi-
system inflammatory disease. The diagnosis of these disorders is
often difficult to establish; in addition, the clinical distinction
between such related disorders may be problematic. It is, how-
ever, crucial to ascertain their diagnosis to avoid unnecessary
invasive investigations and to start appropriate medical treat-
ments. Thanks to the current nosology, progress has been made
in elucidating their molecular basis. Indeed, the MEFV,
TNFRSF1A, and MVK genes have been shown to be involved in
FMF (1, 2), TRAPS (3), and HIDS, respectively (4, 5). Muta-
tions of NALP3 (also called NLRP3, CIAS1, or PYPAF1) are
associated with FCAS, MWS, and CINCA (6, 7), highlighting
that three distinct clinical entities can now be seen as a single
disorder with variable phenotypic expression. The term
cryopyrin-associated periodic syndrome (CAPS) has been pro-
posed to designate this spectrum of autoinflammatory diseases.
In patients with FCAS who usually have the mildest phenotype,
inflammatory attacks are often triggered by generalized expo-
sure to cold. In MWS, attacks are frequently complicated by
progressive hearing loss and renal amyloidosis. CINCA corre-
sponds to the most severe phenotype with CNS manifestations
(e.g., chronic aseptic meningitis, mental retardation, sensori-
neural hearing loss, and visual impairment) associated with
severe arthropathy. In addition, intrafamilial phenotypic heter-
ogeneity has been observed in several families with CAPS
(8–10), which further supports the hypothesis that modifier
genes and/or environmental factors influence the expression of
the disease phenotype.
The great majority of mutations identified so far in HPF genes
correspond to missense mutations, the deleterious effects of
which are very difficult to assess in functional assays. Indeed,
many conflicting data on the function of HPF proteins and
associated mutations have been generated by different teams
even when using similar experimental systems (e.g., 11, 12). In
addition, HPFs remain genetically unexplained in a very large
number of patients (13–16), raising the question of whether one
or several other genes are responsible for these periodic fever
syndromes. Although positional cloning has been of great help
to identify HPF genes, 6 years have passed since the last gene was
shown to be involved in these disorders. The identification of new
genes through linkage studies is becoming difficult because (i)
the great majority of patients referred recently correspond to
sporadic cases, and (ii) many patients present with a combination
of symptoms that overlaps different HPFs and do not fit in any
classification (8, 17–20), precluding the constitution of homo-
geneous groups of patients. Despite these difficulties, the iden-
tification of new disease-causing genes would greatly facilitate
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the management of HPFs in terms of genetic counseling and the
development of effective therapies. In the present study, we
undertook a position-independent candidate gene approach to
determine the molecular basis of a disorder in twin brothers with
no mutations in all known HPF genes, yet presenting with
symptoms overlapping FCAS and MWS. The results obtained
prompted us to perform similar molecular analyses in a second
family with an unexplained periodic fever syndrome.
Results
Clinical Report. In family 1, originating from Guadeloupe, 10-
year-old monozygotic twin brothers (patients II.1 and II.2) have
presented with similar periodic fever syndromes since the first
days of life. They have more than one episode per month, lasting
2–10 days, characterized by high fever (40°C), arthralgias, and
myalgias. Episodes are triggered by generalized exposure to cold,
and urticaria was observed two times in each patient. Both
children have bilateral sensorineural hearing loss. Headache and
lower limb pain occur during and between episodes. C-reactive
protein (CRP) levels are normal during and between attacks;
levels of serum IgD also are normal. Daily treatment with
colchicine has no impact on the frequency of episodes, but
reduces the fever (38°C). The father had attacks lasting 2–3
days during childhood; he currently presents episodes of fever
triggered by mild physical injury and urticaria. His audiogram
revealed no abnormalities. The two children also were treated by
splenectomy for a pyropoikilocytosis due to mutations in the
-spectrin gene.
Patient II.2 (family 2) is a 9-year-old girl who has been
presenting with episodes of fever since the first year of life. Until
the age of 6, she had one attack every 3 weeks lasting 1 week.
Episodes associated high fever (39–41°C), abdominal pain,
vomiting, and arthralgia. Attacks, which were triggered by
generalized exposure to cold, also were characterized by buccal
aphthous ulcers and lymphadenopathy. Headache was rarely
observed. CRP levels were found to be elevated during attacks
(CRP  120/160 mgliter1) and normal between episodes.
Levels of serum IgD were normal. Colchicine had no effect on
the frequency or severity of episodes and was stopped after
several months. Oral corticosteroids reduced the length of
febrile episodes to 3–5 days. At the age of 6, patient II.2 moved
with her family to the South of France; the warmer climate seems
to have reduced the frequency of episodes, with one attack every
2–3 months. Her father had one attack every 2 months from the
age of 5 until the age of 12; these episodes, lasting several hours,
associated fever and abdominal pain.
Identification of Mutations in NALP12. Patients II.1 and II.2 (family
1) display two clinical signs consistent with a diagnosis of CAPS:
sensorineural hearing loss and the triggering effect of cold. We
therefore looked for mutations in NALP3. Nevertheless, se-
quencing of all coding exons and flanking intronic regions did
not reveal any mutation. The subsequent search for mutations in
MEFV, TNFRSF1A, and MVK, the three other genes known to
be involved in HPFs, also was negative.
These observations prompted us to look for a new HPF gene
after a candidate gene approach. Given the disease phenotype,
NALP genes could be considered as good candidates. Among the
14 members of this gene family, we focused on NALP12 (also
known as NLRP12, Monarch-1, or PYPAF7). Screening of all
exons and flanking intronic sequences revealed that the two
children carry the same nonsense mutation in the heterozygous
state: c.850CT (p.Arg284X) located in exon 3 of NALP12 (Fig.
1A). Another sequence variation (c.1352GA) located down-
stream was observed on the same allele (data not shown).
Sequencing of the parents’ DNA showed that the mutated allele
was inherited from the affected father, whereas the healthy
mother displayed a normal sequence (Fig. 1A). Because family
1 originates from an island, we could expect to find the same
mutation in other Guadeloupean patients as a result of a
founding effect. The DNA samples of eight additional Guade-
loupean patients, all but one corresponding to sporadic cases of
genetically unexplained periodic fever syndromes, were then
screened for mutations in NALP12. This analysis revealed in a
young girl (patient II.2, family 2) a sequence variation that was
different from that found in family 1. This variation
Fig. 1. Genealogical trees and mutational analysis of two families with periodic fever syndromes. Filled symbols represent patients with periodic fever
syndromes, and open symbols indicate unaffected family members. Sequencing chromatograms are presented. Red circles indicate the positions of mutations.
Upper and lowercases correspond to exonic and intronic sequences, respectively. Index cases are shown by arrows. (A) Family 1. (B) Family 2.
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(c.20723insT) is a single-base insertion within the donor splice
site of intron 3 (Fig. 1B). Screening of NALP3, MEFV,
TNFRSF1A, and MVK did not reveal any other defect in the
patient. This mutation also was found in the heterozygous state
in her father (patient I.1, family 2), who presented with milder
clinical manifestations, but was not identified in her mother or
half-sister (Fig. 1B). The nonsense and splice-site mutations
were not found in 104 chromosomes from Guadeloupean
controls.
Impact of c.20723insT on Splicing. Because the mutation identified
in patient II.2 (family 2) involves a donor splice site and no fresh
blood sample was available for this patient, we studied the splicing
of NALP12 transcripts after transfection of WT and mutated
NALP12 minigenes in HEK293T cells. RT-PCR amplification of
NALP12 transcripts spanning exons 2–4 from cells transfected with
pNALP12g-WTyielded an1,900-bp amplicon, which is consistent
with normal splicing of introns 2 and 3 (Fig. 2A Top). In contrast,
the c.20723insT mutation produced a smaller product (Fig. 2A
Top). To better characterize each isoform, we amplified cDNA
fragments encompassing the end of exons 3 and 4. The WT
construct generated a molecular species of 632 bp, whereas a single
molecular species of 450 bp was generated with pNALP12g-
c.20723insT (Fig. 2A Middle). Direct sequencing of the latter
PCR product revealed that the transcript is deleted from the last
170 bp of exon 3 (Fig. 2B), thereby unveiling the activation of a
cryptic donor splice site located upstream in exon 3 (Fig. 2C). This
splicing defect results in a frameshift that introduces 11 new amino
acids, followed by a termination codon at position 646 (NALP12-
Val635ThrfsX12).
Functional Consequences of the Identified NALP12 Mutations. NALP
proteins comprise an N-terminal pyrin domain (PYD), a central
nucleotide-binding site (NBS), and C-terminal leucin-rich repeats
(LRRs) (Fig. 3A). The p.Arg284X mutation, located within the
NBS of NALP12, and the p.Val635ThrfsX12 mutation, located
between the NBS and LRRs, would generate proteins deleted of
regions highly conserved throughout evolution (Fig. 3A), strongly
suggesting that these defects are deleterious.
This observation prompted us to study the role played by WT
NALP12 on NF-B signaling and to assess the functional
consequences of the two identifiedNALP12mutations.NALP12
is expressed primarily in cells of the myelomonocytic lineage (11,
21). Because it is known that endogenous NALP12 is difficult to
detect in those cells (22), we transfected HEK293T cells with
pNALP12-WT, pNALP12-Arg284X, or pNALP12-
Val635ThrfsX12. The data obtained revealed that NALP12-WT
strongly inhibits the NF-B activation induced by p65 (Fig. 3B).
Most importantly, under similar experimental conditions, the
inhibitory properties of the protein carrying the p.Arg284X
mutation are dramatically reduced (Fig. 3B). Similarly, we
observed that the NF-B-suppressive property of NALP12-
Val635ThrfsX12 is lower than that of the WT protein (Fig. 3B).
Similar results were obtained when we induced NF-B activity
by TNF treatment or through the coexpression of NALP12
with IRAK1 (data not shown).
Discussion
This study identifies the first disease-causing mutations in
NALP12 in patients with periodic fever syndromes. Based on in
vitro studies and in silico analyses, we elected NALP12 as a
relevant candidate gene for HPFs: (i) it is expressed in my-
Fig. 2. Impact of the c.20723insT mutation on NALP12 splicing. (A) (Upper) RT-PCR amplifications of NALP12 transcripts from HEK293T cells transfected with
pNALP12g-WT and pNALP12g-c.20723insT mini-genes. -actin was amplified on the same sample as control. L, 1-kbmarker; EV, empty vector. (Lower) The
diagram indicates the location of the primers used in RT-PCR experiments (arrows). Exons and introns are represented by gray boxes and thin lines, respectively.
The c.20723insT insertion is indicated by an arrowhead. (B) Chromatograms obtained after sequencing of the RT-PCR products presented inA (middle gel) and
corresponding to the exon 3–exon 4 junction. (C) Schematic representation of the effect of c.20723insT on NALP12 splicing. (Upper) Normal splicing of intron
3. (Lower) Splicing resulting from the c.20723insT mutation, indicated by a black arrowhead. Gray boxes correspond to NALP12 exons; upper and lowercases
correspond to exonic and intronic sequences, respectively. The cryptic donor splice site is indicated in italics.
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elomonocytic cells (11); (ii) its nucleotide sequence is highly
similar to that of NALP3, with 58% identity; (iii) among NALPs,
the NBS of NALP12 is the most closely related to the one of
NALP3 (23), which contains most mutations identified in pa-
tients with FCAS, MWS, and CINCA; and (iv) NALP12 is
believed to regulate inflammatory and immunological pathways
(11, 21, 22).
Sequencing of NALP12 revealed a heterozygous nonsense
mutation (c.850CT, p.Arg284X) in identical twin brothers
presenting with symptoms overlapping FCAS andMWS, thereby
providing a clear-cut answer to the suspected genetic heteroge-
neity of these disorders (15, 24). This nonsensemutation also was
found in their father, who displays a milder phenotype. A second
NALP12 mutation (c.20723insT) was identified in a patient
presenting with a periodic fever syndrome, including clinical
manifestation of FCAS. This mutation, affecting the donor
splice site of intron 3, activates a cryptic splice site located
upstream in exon 3 and results in a frameshift, followed by a
premature stop codon. This splice mutation also was found in her
father, who presented with periodic fever symptoms during
childhood. Altogether these data show in two independent
families the segregation of the identified mutations with the
disease, such data being consistent with an autosomal-dominant
mode of inheritance of NALP12-associated periodic fever syn-
dromes. Noteworthy, the three affected children investigated
herein share several phenotypic similarities: (i) the disease
started during the first year of life; (ii) the patients present more
than one attack per month; (iii) episodes are triggered by
generalized exposure to cold; and (iv) attacks that last several
days associate high fever (40°C), arthralgia, and headache in
the two families. However, the patients also have distinguishing
clinical manifestations: urticaria and sensorineural hearing loss
were only observed in family 1, in whom acute-phase reactants
were not elevated during crises, whereas aphthous ulcers and
lymphadenopathy were noticed in patient II.2 from family 2.
Such interfamilial phenotypic heterogeneity is frequently ob-
served in HPFs (19, 20, 25–27); in this regard, it has even been
shown that a same mutation (in NALP3) can be associated with
different CAPSs (8, 27, 28). Furthermore, phenotypic hetero-
geneity also has been shown to be intrafamilial in this pathology,
especially in NALP3-associated disorders (8–10). As for acute-
phase reactants, although the majority of studies describes a
marked increase in CRP levels in a patient with HPFs (29),
Hoffman et al. (30) reported normal CRP concentrations in a
Fig. 3. Functional consequences of the identified mutations on NALP12 function. (A) Schematic representation of human NALP12 and partial alignment of its
amino acid sequence (GenBank accession no. NP653288) with corresponding sequences in other species (chimpanzee, XP524387.2; mouse, XP978890.1; rat,
XP001066862.1; dog, Ensemble accession no. ENSCAFP00000003989). Alignment with human NALP3 (GenBank accession no. NP004886.3) is also presented. The
Arg-284 residue is indicated by an asterisk, and the Val-635 residue is indicated by an arrowhead. Black shading indicates identical residues, and gray shading
indicates similar residues. PYD, pyrin domain; NBS, nucleotide-binding site; LRR; leucin-rich repeats. (B) Effect of NALP12-WT and NALP12-mutated proteins on
NF-B signaling. HEK293T cells were transfected with 100 ng of the pNF-B-LUC luciferase reporter and with 800 ng of plasmids encoding NALP12-WT,
NALP12-Arg284X, or NALP12-Val635ThrfsX12 as indicated. The NF-B signaling pathway was induced by transfection of 100 ng of p65. Then, 24 h after
transfection, luciferase activities were determined on cell lysates; results of one representative experiment done in triplicate are expressed as means SD. NALP12
proteins were quantitated by Western blot analysis on the same protein lysates. Membranes were reprobed with anti--tubulin antibodies as a loading control.
EV, empty vector.
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patient presenting with FCAS. Other cases of patients with slight
to moderate elevation of inflammatory markers have been
described (8, 31). Overall, such clinical and biological differences
in HPFs may reflect the effect of distinct mutations and/or result
from different genetic backgrounds or environmental factors. In
addition, even if the similarities between NALP3 and NALP12
are numerous, our data argue against functional redundancy
because a single mutation in NALP12 is sufficient to induce an
autoinflammatory disease.
The demonstration of the involvement of NALP12 in HPFs is
supported by additional lines of evidence. (i) The two identified
sequence variations were not found in a population sample of the
same origin. (ii) Most importantly, such nonsense and splice
mutations are nonambiguous defects; in this regard, it is impor-
tant to emphasize that nearly all mutations reported so far in
HPF genes are missense mutations, the deleterious effects of
which are particularly difficult to assess. (iii) The two mutations
affect evolutionarily conserved domains. (iv) Both mutations
induce a clear reduction of the inhibitory properties of NALP12
on NF-B signaling, in keeping with a loss of function. In
addition, coexpression studies revealed that NALP12-mutated
proteins do not interfere with the function of the normal isoform
(data not shown). Taken together, these observations are con-
sistent with a dominant mode of expression through haploin-
sufficiency. Consistent with our observation that NALP12 acts
as an NF-B inhibitor, Williams et al. (22) demonstrated sup-
pressive properties of NALP12 on NF-B signaling induced by
various agents (including TNF and IRAK1). We also showed
an inhibitory effect of NALP12 on NF-B activity induced by
p65, a result that, for unknown reasons, was not observed by
these authors.
NALP proteins are part of the larger family of CATER-
PILLER proteins (also known as NLRs) characterized by NBS
and LRR domains located downstream of various N-terminal
regions. Like TLRs, NLRs have recently been identified as
proteins involved in host defense against pathogens: TLRs are
primarily cell-surface receptors characterized by extracellular
LRRs sensing pathogen molecules and triggering inflammatory
and immune responses, whereas NLRs are believed to be
intracellular LRR-containing proteins involved in similar sig-
naling pathways, although information about their function is
still relatively scarce (32).
Five NLR genes have been involved in human pathology:
NALP7 in hydatidiform mole (33), NALP1 in vitiligo-associated
autoimmune diseases (34), NALP3 in HPFs (7, 35), CIITA in
bare lymphocyte syndrome (36) and multiple sclerosis (37), and
NOD2 in Crohn’s disease and Blau syndrome (38, 39). Our study,
which establishes NALP12 as a gene responsible for periodic
fever syndromes, underlines the role of the NALP gene family in
the pathogenesis of the recently recognized continuum of auto-
immune–autoinflammatory diseases (40). The identification of
NALP12 mutations in patients with autoinflammatory disease
also demonstrates the crucial role of NALP12 in inflammatory
signaling pathways, thereby assigning a precise function to this
particular member of the emerging family of NALP proteins,
whose putative biological properties are currently inferred es-
sentially through in vitromeans. However, given the documented
role of NOD2 and CIITA in both Mendelian and multifactorial
disorders, our data, which should reveal ways to manage periodic
fever syndromes, also raise the question of the possible role of
NALP12 in common multifactorial diseases.
Materials and Methods
Patients. This study was approved by the local ethics committee (Comite´
Consultatif de Protection des Personnes se pre`tant a` une Recherche Biome´di-
cale–Henri Mondor, Cre´teil, France). Informed written consent for genetic
studies was given by all patients or their parents. Clinical features were
recorded on a standardized form.
Molecular Analysis. gDNA was extracted from peripheral blood leukocytes. All
coding exons and flanking intronic sequences of MEFV, TNFRSF1A, MVK,
NALP3, and NALP12 were amplified by PCR and sequenced. The presence of
mutations was confirmed by forward and reverse sequencing.
Plasmid Constructs. The full-length NALP12 cDNA coding sequence was cloned
into pcDNA3 to generate pNALP12-WT. Site-directed mutagenesis (Strat-
agene) was performed to generate pNALP12-Arg284X and pNALP12-
Val635ThrfsX12.
Because no fresh blood sample was available for the study of NALP12
transcripts, we constructed NALP12 mini-genes. Genomic fragments spanning
exons 2–4 and flanking intronic sequences were amplified by PCR; normal
gDNA (Roche) and DNA of patient II.2 (family 2) were used as a template. The
resulting products were cloned into pcDNA3.1-V5HisTopo (Invitrogen) to
generate pNALP12g-WT encoding the normal sequence and pNALP12g-
c.20723insT corresponding to the mutated allele identified in patient II.2
(family 2). The NF-B p65 expression plasmid has been described previously
(41). All constructs were checked by sequencing.
Splicing Assay. pNALP12g-WT and pNALP12g-c.20723insT were transfected
into HEK293T cells. Then 24 h after transfection, total RNA was extracted (RNA
PLUS kit; Qbiogene). cDNAs were synthesized by random-primed reverse
transcription (Sensiscript kit; Qiagen). PCR amplifications of NALP12 and
-actin transcripts were performed by using different combinations of for-
ward and reverse primers. Primer sequences for PCR amplifications are avail-
able on request.
NF-B Luciferase Assay. HEK293T cells were transfected (LipofectAMINE; In-
vitrogen) with 100 ng of pNF-B-LUC (Stratagene), 100 ng of p65, 100 ng of
pIRAK1, and 800 ng of NALP12 expression plasmids as indicated. Cells were
treated with 10 ng/ml TNF for 24 h or left untreated. Luciferase activities
were determined on cell lysates from triplicate cultures (Promega assay) and
normalized to protein concentration (Coomassie Plus Protein Assay; Pierce).
Western blotting was performed with anti-NALP12 (Tebu-Bio), anti--tubulin
antibodies (DM1A, Sigma–Aldrich), and HRP-conjugated anti-mouse antibod-
ies (Sigma–Aldrich). Detection was performed with chemiluminescence re-
agents (GE Healthcare).
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